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BACKGROUND: Canagliflozin reduces the risk of kidney failure in 
patients with type 2 diabetes mellitus and chronic kidney disease, but 
effects on specific cardiovascular outcomes are uncertain, as are effects in 
people without previous cardiovascular disease (primary prevention).
METHODS: In CREDENCE (Canagliflozin and Renal Events in Diabetes 
With Established Nephropathy Clinical Evaluation), 4401 participants 
with type 2 diabetes mellitus and chronic kidney disease were randomly 
assigned to canagliflozin or placebo on a background of optimized 
standard of care.
RESULTS: Primary prevention participants (n=2181, 49.6%) were younger 
(61 versus 65 years), were more often female (37% versus 31%), and had 
shorter duration of diabetes mellitus (15 years versus 16 years) compared 
with secondary prevention participants (n=2220, 50.4%). Canagliflozin 
reduced the risk of major cardiovascular events overall (hazard ratio [HR], 
0.80 [95% CI, 0.67–0.95]; P=0.01), with consistent reductions in both the 
primary (HR, 0.68 [95% CI, 0.49–0.94]) and secondary (HR, 0.85 [95% CI,  
0.69–1.06]) prevention groups (P for interaction=0.25). Effects were also 
similar for the components of the composite including cardiovascular 
death (HR, 0.78 [95% CI, 0.61–1.00]), nonfatal myocardial infarction 
(HR, 0.81 [95% CI, 0.59–1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 
0.56–1.15]). The risk of the primary composite renal outcome and the 
composite of cardiovascular death or hospitalization for heart failure were 
also consistently reduced in both the primary and secondary prevention 
groups (P for interaction >0.5 for each outcome).
CONCLUSIONS: Canagliflozin significantly reduced major cardiovascular 
events and kidney failure in patients with type 2 diabetes mellitus and 
chronic kidney disease, including in participants who did not have 
previous cardiovascular disease.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. 
Unique identifier: NCT02065791.
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Patients with type 2 diabetes mellitus and chronic kidney disease are at increased risk of cardiovas-cular events.1 Sodium glucose cotransporter 2 
(SGLT2) inhibitors have been shown to be noninferior 
to placebo2 or superior to placebo3,4 in reducing car-
diovascular outcomes, including cardiovascular death, 
nonfatal myocardial infarction, or nonfatal stroke, in 
patients with type 2 diabetes mellitus. In addition, car-
diovascular death or hospitalization for heart failure 
has been reduced with canagliflozin compared with 
placebo.4
A systematic review of 3 large cardiovascular out-
come trials in participants with type 2 diabetes melli-
tus showed that SGLT2 inhibition reduced the risk of 
cardiovascular death, myocardial infarction, or stroke 
by 11% (hazard ratio [HR], 0.89 [95% CI, 0.83–0.96]; 
P=0.0014).5 However, this effect was restricted to a 
14% reduction in patients with established cardiovas-
cular disease (HR, 0.86 [95% CI, 0.80–0.93]), with no 
difference observed in patients without previous car-
diovascular disease but with multiple risk factors for 
cardiovascular disease (HR, 1.00 [95% CI, 0.87–1.16]; 
P for interaction=0.0501). Directionally different effects 
on stroke have also been reported from previous trials, 
as have varying magnitudes of benefit for cardiovascu-
lar death.2–4 Effects on renal and heart failure outcomes 
showed consistent benefit in both primary and second-
ary prevention groups.5
The CREDENCE trial (Canagliflozin and Renal Events 
in Diabetes With Established Nephropathy Clinical Eval-
uation) showed that canagliflozin prevented renal and 
cardiovascular outcomes in patients with type 2 diabe-
tes mellitus and chronic kidney disease.6 Although par-
ticipants with and without cardiovascular disease were 
enrolled, it is expected that the presence of chronic kid-
ney disease would result in high cardiovascular risk in 
the primary prevention cohort as well, so the effects 
on major cardiovascular events in this population are of 
particular interest.7 This article describes detailed analy-
ses of individual cardiovascular outcomes and looks at 
effects on a range of outcomes in participants with and 




Data from this study will be made available in the public 
domain via the Yale University Open Data Access Project 
(http://yoda.yale.edu/) once the product and relevant indica-
tion studied have been approved by regulators in the United 
States and European Union and the study has been com-
pleted for 18 months.
Study Design and Organization
Details of the CREDENCE study design and the primary results 
have been published previously.6,8 CREDENCE was a random-
ized, double-blind, placebo-controlled, multicenter interna-
tional clinical trial. The study was approved by the necessary 
regulatory authorities and ethics committees. The study was 
registered at ClinicalTrials.gov (https://www.clinicaltrials.gov; 
NCT02065791).
The trial was funded and sponsored by Janssen Research 
& Development, LLC and was an academic/industry collabora-
tion with an academic-led Steering Committee (online-only 
Data Supplement) and an academic research group, George 
Clinical. Analyses were performed by the sponsor and inde-
pendently confirmed at George Clinical with the use of origi-
nal data. The first author drafted the manuscript. All authors 
contributed to revisions and agreed to submit the paper.
Participants
The criteria for inclusion and exclusion have been previously 
published (online-only Data Supplement).6,8 In brief, partici-
pants were eligible if they were ≥30 years of age, had a clinical 
diagnosis of type 2 diabetes mellitus with a glycated hemoglo-
bin level of 6.5% to 12.0%, and had chronic kidney disease, 
with an estimated glomerular filtration rate (eGFR; calculated 
with the CKD-EPI [Chronic Kidney Disease Epidemiology 
Collaboration] formula) of 30 to <90 mL·min−1·1.73 m−2 
and albuminuria (urine albumin:creatinine ratio of >300 to 
5000 mg/g [>33.9–565.6 mg/mmol]). All participants were to 
be on stable maximum tolerated labeled daily dose of angio-
tensin-converting enzyme inhibitor or angiotensin recep-
tor blocker for ≥4 weeks before randomization. Treatment 
with dual angiotensin-converting enzyme inhibitor and 
Clinical Perspective
What Is New?
• Previous studies and a systematic review have 
indicated that the effects of sodium glucose 
cotransporter 2 inhibition are uncertain in people 
without previous cardiovascular disease (primary 
prevention).
• The CREDENCE trial (Canagliflozin and Renal 
Events in Diabetes With Established Nephropathy 
Clinical Evaluation) enrolled participants with and 
without previous cardiovascular disease.
• These analyses demonstrate robust and consistent 
reductions in cardiovascular and renal outcomes in 
participants with and without previous cardiovas-
cular disease, with no increased risk of fractures or 
amputations.
What Are the Clinical Implications?
• These data support the initiation of canagliflozin 
in a much broader patient population with type 
2 diabetes mellitus, including those with glycated 
hemoglobin as low as 6.5% and patients with esti-
mated glomerular filtration rate between 30 and 
45 mL·min−1·1.73 m−2, with expected reductions in 
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angiotensin receptor blocker, direct renin inhibitor, or miner-
alocorticoid receptor antagonist at the time of enrollment was 
not allowed. Classification of primary or secondary prevention 
was based on cardiovascular medical histories collected by 
investigators during the screening period. Participants were 
classified as belonging to the secondary prevention cohort 
if they had a history of coronary, cerebrovascular, or periph-
eral vascular disease. All other participants were classified as 
belonging to the primary prevention cohort. All participants 
provided informed consent.
Study Procedures
Participants were randomly assigned in double-blind fashion 
(1:1) to canagliflozin 100 mg daily or matching placebo with 
stratification by screening eGFR categories (30–<45, 45–<60, 
and 60–<90 mL·min−1·1.73 m−2). After randomization, study 
visits were conducted at weeks 3, 13, and 26 and then alter-
nated between telephone calls and in-clinic visits at 13-week 
intervals.
Outcomes
The efficacy outcomes for these analyses included those in 
the prespecified hierarchical testing sequence detailed previ-
ously.6 All deaths, cardiovascular events, and renal outcomes, 
as well as all suspected pancreatitis, fractures, renal cell car-
cinoma, and diabetic ketoacidosis events, were reviewed by 
adjudication committees blinded to therapy. The definitions 
used for the clinical events have been published previously.6,8
Statistical Analyses
The study was stopped early on the basis of the recommenda-
tion of the independent data monitoring committee. Details 
of the stopping criteria and other statistical considerations 
have been reported previously.6 Analyses of the primary and 
secondary outcomes were planned for hierarchical testing, 
with subgroup analyses for the primary outcome prespeci-
fied in both cohorts. Additional analyses are post hoc. All 
analyses of the effects of canagliflozin compared with pla-
cebo on cardiovascular and renal outcomes were based on 
the intention-to-treat principle using all follow-up time for 
all randomized participants. Renal, cardiovascular, mortality, 
and safety outcomes were analyzed with a stratified Cox pro-
portional hazards regression model, according to the eGFR 
category at screening. HRs and 95% CIs were estimated 
for participants assigned to canagliflozin versus participants 
assigned to placebo separately for the primary and secondary 
prevention cohorts, and P values are shown for outcomes that 
were significantly reduced according to the original hierarchi-
cal testing strategy.6 The HRs for cardiovascular disease and 
kidney disease outcomes comparing the placebo groups in 
the secondary prevention cohort versus the primary preven-
tion cohort were calculated to remove potential confounding 
effects of canagliflozin treatment and to estimate the relative 
risk as part of the natural disease course. Subgroup analy-
ses within each prevention cohort were assessed by tests for 
the multiplicative interaction term between the randomized 
treatment group and the subgroup in stratified Cox propor-
tional hazards models without adjustment for multiple test-
ing. Safety outcomes were analyzed with an on-treatment 
approach (based on patient time and events accrued while on 
study drug or within 30 days of study drug discontinuation) 
except for fracture, cancer, and amputation events, which 
were assessed using all follow-up time.
Within each prevention cohort, the number of patients 
who needed to be treated to prevent 1 event during 2.5 years 
was calculated as the reciprocal of the between-group differ-
ence in cumulative incidence at 2.5 years on the basis of the 
Kaplan–Meier curve. The 95% CIs for the numbers needed 
to treat (NNT) were calculated according to the method of 
Altman et al.9 All analyses were performed with the use of 
SAS software, version 9.4 (SAS Institute).
RESULTS
In CREDENCE, a total of 4401 participants were ran-
domized in 34 countries. The mean follow-up was 2.62 
years. Vital status was known for all but 6 participants 
(0.1%) at the end of the study.6
Cardiovascular Outcomes
Cardiovascular outcomes by treatment assignment are 
shown for the overall population in Figure  1. Cana-
gliflozin compared with placebo reduced the risk of 
cardiovascular death, nonfatal myocardial infarction, or 
nonfatal stroke (9.9% versus 12.2%; HR, 0.80 [95% 
CI, 0.67–0.95]; P=0.01), with similar results for car-
diovascular death (5.0% versus 6.4%; HR, 0.78 [95% 
CI, 0.61–1.00]), nonfatal myocardial infarction (3.2% 
versus 4.0%; HR, 0.81 [95% CI, 0.59–1.10]), and 
nonfatal stroke (2.4% versus 3.0%; HR, 0.80 [95% 
CI, 0.56–1.15]). Canagliflozin also lowered the risk of 
cardiovascular death, nonfatal myocardial infarction, 
nonfatal stroke, hospitalization for heart failure, or hos-
pitalization for unstable angina (12.4% versus 16.4%; 
HR, 0.74 [95% CI, 0.63–0.86]). Canagliflozin reduced 
the risk of the composite of cardiovascular death or hos-
pitalization for heart failure (8.1% versus 11.5%; HR, 
0.69 [95% CI, 0.57–0.83]; P<0.001) and hospitalization 
for heart failure (4.0% versus 6.4%; HR, 0.61 [95% CI, 
0.47–0.80]; P<0.001) in the overall population.6
Primary and Secondary Prevention 
Patient Characteristics
A total of 2181 participants (49.6%) had no history of 
documented cardiovascular disease at entry and were 
in the primary prevention group, and 2220 participants 
(50.4%) were in the secondary prevention group. The 
baseline demographics are shown in Table  1 for the 
primary and secondary prevention groups and by treat-
ment assignment. Primary prevention participants were 
younger (61.4 years versus 64.6 years) and more often 
female (36.6% versus 31.3%) and Asian (24.4% versus 
15.5%) with a shorter duration of diabetes mel-
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secondary prevention participants. Primary and sec-
ondary prevention participants had similar mean eGFR 
(56.8 mL·min−1·1.73 m−2 versus 55.5 mL·min−1·1.73 m−2) 
and median urine albumin:creatinine ratio (943 mg/g 
versus 903 mg/g).
Cardiovascular Outcomes by Primary and 
Secondary Prevention
In placebo-treated patients, cardiovascular death or 
hospitalization for heart failure occurred more frequent-
ly in the secondary prevention group compared with 
the primary prevention group (15.1% versus 7.9%; HR, 
1.95 [95% CI, 1.51–2.53]), as did major cardiovascular 
events (cardiovascular death, nonfatal myocardial in-
farction, or nonfatal stroke; 16.1% versus 8.3%; HR, 
1.97 [95% CI, 1.53–2.54]).
The effects of the randomized treatment assignment 
on cardiovascular outcomes are shown for the primary 
and secondary prevention groups in Figures 2 and 3. 
Canagliflozin reduced major cardiovascular events, with 
a meaningful reduction in this outcome for the primary 
prevention group (HR, 0.68 [95% CI, 0.49–0.94]) that 
was consistent with the effect in the secondary pre-
vention groups (HR, 0.85 [95% CI, 0.69–1.06]; P for 
interaction=0.25). Consistency in the effects was also 
observed across all other cardiovascular end points for 
both the primary and secondary prevention groups (all 
P for interaction >0.10).
Renal Outcomes by Primary and 
Secondary Prevention
In placebo-treated patients, the risk of the primary end 
point (composite of end-stage kidney disease, dou-
bling serum creatinine, or renal or cardiovascular death) 
was comparable between the secondary prevention 
group and the primary prevention group (16.4% ver-
sus 14.5%; HR, 1.11 [95% CI, 0.89–1.37]). The effects 
of the randomized treatment assignment on renal out-
comes are shown for the primary and secondary pre-
vention groups in Figure 3. Canagliflozin reduced renal 
outcomes, with no evidence of heterogeneity in the pri-
mary and secondary prevention groups. All interaction 
P values were not significant.
Cardiovascular Outcomes Across Other 
Patient Subgroups
Figure 4 shows the composite of cardiovascular death, 
nonfatal myocardial infarction, or nonfatal stroke 
in the overall population for subgroups defined by 
A B
C D
Figure 1. Effects of canagliflozin on cardiovascular outcomes in the overall population. 
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Table 1. Baseline Demographic and Disease Characteristics of Primary and Secondary Prevention Cohorts in CREDENCE*
Characteristic













Age, y 61.1±9.7 61.7±9.4 61.4±9.6 64.6±8.2 64.6±8.9 64.6±8.6
Female sex, n (%) 405 (37.2) 394 (36.1) 799 (36.6) 357 (32.1) 338 (30.5) 695 (31.3)
Race, n (%)       
  White 646 (59.3) 640 (58.6) 1286 (59.0) 841 (75.6) 804 (72.6) 1645 (74.1)
  Black or African American 58 (5.3) 63 (5.8) 121 (5.5) 54 (4.9) 49 (4.4) 103 (4.6)
  Asian 265 (24.3) 268 (24.5) 533 (24.4) 160 (14.4) 184 (16.6) 344 (15.5)
  Other†‡ 120 (11.0) 121 (11.1) 241 (11.0) 58 (5.2) 70 (6.3) 128 (5.8)
Region, n (%)       
  North America 325 (29.8) 337 (30.9) 662 (30.4) 249 (22.4) 271 (24.5) 520 (23.4)
  Central/South America 235 (21.6) 254 (23.3) 489 (22.4) 241 (21.7) 211 (19.1) 452 (20.4)
  Europe 186 (17.1) 177 (16.2) 363 (16.6) 268 (24.1) 233 (21.0) 501 (22.6)
  Rest of the world 343 (31.5) 324 (29.7) 667 (30.6) 355 (31.9) 392 (35.4) 747 (33.6)
Ethnicity, n (%)‡       
  Hispanic/Latino 415 (38.1) 430 (39.4) 845 (38.7) 302 (27.1) 276 (24.9) 578 (26.0)
  Not Hispanic/Latino 639 (58.7) 637 (58.3) 1276 (58.5) 797 (71.6) 820 (74.1) 1617 (72.8)
  Not reported/unknown 35 (3.2) 25 (2.3) 60 (2.8) 14 (1.3) 11 (1.0) 25 (1.1)
Current smoker, n (%) 172 (15.8) 143 (13.1) 315 (14.4) 169 (15.2) 155 (14.0) 324 (14.6)
History of hypertension, n (%) 1046 (96.1) 1048 (96.0) 2094 (96.0) 1085 (97.5) 1081 (97.7) 2166 (97.6)
History of heart failure, n (%) 63 (5.8) 58 (5.3) 121 (5.5) 266 (23.9) 265 (23.9) 531 (23.9)
History of myocardial infarction, n (%) 0 0 0 215 (19.3) 227 (20.5) 442 (19.9)
History of stroke, n (%) 0 0 0 225 (20.2) 233 (21.0) 458 (20.6)
Duration of diabetes mellitus, y 14.8±8.4 15.5±8.4 15.2±8.4 16.3±8.9 16.5±8.7 16.4±8.8
Drug therapy, n (%)       
  Insulin 691 (63.5) 681 (62.4) 1372 (62.9) 761 (68.4) 751 (67.8) 1512 (68.1)
  Sulfonylurea 309 (28.4) 337 (30.9) 646 (29.6) 303 (27.2) 319 (28.8) 622 (28.0)
  Metformin 670 (61.5) 662 (60.6) 1332 (61.1) 606 (54.4) 607 (54.8) 1213 (54.6)
  GLP-1 receptor agonist 40 (3.7) 49 (4.5) 89 (4.1) 49 (4.4) 45 (4.1) 94 (4.2)
  DPP-4 inhibitor 211 (19.4) 211 (19.3) 422 (19.3) 167 (15.0) 162 (14.6) 329 (14.8)
  Statin 708 (65.0) 684 (62.6) 1392 (63.8) 830 (74.6) 814 (73.5) 1644 (74.1)
  Antithrombotic§ 477 (43.8) 453 (41.5) 930 (42.6) 864 (77.6) 830 (75.0) 1694 (76.3)
  RAAS inhibitor 1089 (100) 1088 (99.6) 2177 (99.8) 1112 (99.9) 1106 (99.9) 2218 (99.9)
  β-blocker 331 (30.4) 316 (28.9) 647 (29.7) 552 (49.6) 571 (51.6) 1123 (50.6)
  Diuretic 458 (42.1) 471 (43.1) 929 (42.6) 568 (51.0) 560 (50.6) 1128 (50.8)
Microvascular disease history, n (%)       
  Retinopathy 407 (37.4) 425 (38.9) 832 (38.1) 528 (47.4) 522 (47.2) 1050 (47.3)
  Neuropathy 430 (39.5) 443 (40.6) 873 (40.0) 647 (58.1) 627 (56.6) 1274 (57.4)
History of amputation, n (%) 0 0 0 119 (10.7) 115 (10.4) 234 (10.5)
Body mass index, kg/m2 31.2±6.4 31.0±6.3 31.1±6.3 31.6±6.0 31.6±6.1 31.6±6.0
Systolic blood pressure, mm Hg 139.0±15.9 139.8±15.9 139.4±15.9 140.6±15.2 140.5±15.4 140.5±15.3
Diastolic blood pressure, mm Hg 79.0±9.2 78.5±9.5 78.8±9.4 77.5±9.4 78.2±9.3 77.8±9.3
Glycated hemoglobin, % 8.2±1.3 8.3±1.3 8.3±1.3 8.3±1.3 8.3±1.3 8.3±1.3
Cholesterol, mg/dL (mmol/L)       
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 demographics, clinical history, and baseline laboratory 
values. The treatment effect with canagliflozin com-
pared with placebo was consistent across subgroups, 
including across categories of renal function defined 
by eGFR and urine albumin:creatinine ratio. However, 
a borderline greater benefit was seen in people with a 
history of amputation compared with those without (P 
for interaction=0.06; all other interaction P>0.20).
Safety Outcomes
Figure I in the online-only Data Supplement shows the re-
sults for adverse events, serious adverse events, and other 
adverse events of interest for the primary and second-
ary prevention groups. No difference in fracture risk with 
canagliflozin (HR, 0.98 [95% CI, 0.70–1.37]) compared 
with placebo was observed in the overall population.6 
Similar findings were seen in the primary and secondary 
prevention groups. Overall, no difference in amputation 
events was observed with canagliflozin compared with 
placebo (HR, 1.11 [95% CI, 0.79–1.56]),6 with no hetero-
geneity in the primary and secondary prevention groups.
Numbers Needed to Treat
Table 2 shows the number of participants who needed 
to be treated for 2.5 years to prevent 1 event, with 95% 
CIs shown only when they do not include 0. The NNT 
for end-stage kidney disease, doubling of serum creati-
nine, or renal or cardiovascular death was 19 (95% CI, 
12–40) in the primary and 26 (95% CI, 15–96) in the 
secondary prevention group. For cardiovascular death 
or hospitalization for heart failure, the NNT was 53 in 
the primary and 21 (95% CI, 13–47) in the secondary 
prevention group. For cardiovascular death, nonfatal 
myocardial infarction, or nonfatal stroke, the NNT was 
36 (95% CI, 20–186) in the primary and 44 in the sec-
ondary prevention group.




































  Ratio of LDL to HDL 2.3±1.2 2.3±1.1 2.3±1.1 2.3±1.1 2.2±1.0 2.3±1.0
eGFR, mL·min−1·1.73 m−2‖ 57.1±18.7 56.6±18.4 56.8±18.5 55.6±17.6 55.5±18.2 55.5±17.9
  eGFR ≥90 mL·min−1·1.73 m−2, n (%) 56 (5.1) 57 (5.2) 113 (5.2) 49 (4.4) 49 (4.4) 98 (4.4)
  eGFR ≥60–<90 mL·min−1·1.73 m−2, n (%) 407 (37.4) 392 (35.9) 799 (36.6) 381 (34.3) 378 (34.1) 759 (34.2)
  eGFR ≥45–<60 mL·min−1·1.73 m−2, n (%) 294 (27.0) 321 (29.4) 615 (28.2) 336 (30.2) 315 (28.5) 651 (29.3)
  eGFR ≥30–<45 mL·min−1·1.73 m−2, n (%) 289 (26.5) 277 (25.4) 566 (26.0) 305 (27.4) 320 (28.9) 625 (28.2)
  eGFR ≥15–<30 mL·min−1·1.73 m−2, n (%) 43 (3.9) 45 (4.1) 88 (4.0) 40 (3.6) 44 (4.0) 84 (3.8)
  eGFR <15 mL·min−1·1.73 m−2, n (%) 0 0 0 1 (0.1) 1 (0.1) 2 (0.1)
Median urine albumin:creatinine ratio  
(IQR), mg/g
956 (446–1820) 937 (456–1850) 943 (450–1841) 883 (477–1790) 928 (493–1898) 903 (484–1827)
  Normoalbuminuria, n (%)¶ 10 (0.9) 8 (0.7) 18 (0.8) 6 (0.5) 7 (0.6) 13 (0.6)
  Microalbuminuria, n (%)¶ 124 (11.4) 134 (12.3) 258 (11.8) 127 (11.4) 111 (10.0) 238 (10.7)
  Nonnephrotic-range macroalbuminuria,  
n (%)#
841 (77.2) 824 (75.5) 1665 (76.3) 861 (77.4) 845 (76.3) 1706 (76.8)
  Nephrotic-range macroalbuminuria, n (%)** 114 (10.5) 126 (11.5) 240 (11.0) 119 (10.7) 144 (13.0) 263 (11.8)
CREDENCE indicates Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation; DPP-4, dipeptidyl peptidase-4; eGFR, estimated 
glomerular filtration rate; GLP-1, glucagon-like peptide-1; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; and RAAS, renin 
angiotensin aldosterone system.
*Plus-minus values are mean±SD.
†Includes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple, other, unknown, and not reported.
‡Percentages may not total 100.0% because of rounding.
§Includes anticoagulation and antiplatelet agents, including aspirin.
‖Values for baseline eGFR categories calculated on the basis of n=2219 for the total secondary prevention cohort (1112 in the canagliflozin group and 1107 in 
the placebo group).
¶Eligibility was based on screening urine albumin:creatinine ratio >300 to ≤5000 mg/g.
#Nonnephrotic-range macroalbuminuria is defined as urine albumin:creatinine ratio >300 and ≤3000 mg/g.
**Nephrotic-range macroalbuminuria is defined as urine albumin:creatinine ratio >3000 mg/g.
Table 1. Continued
Characteristic
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The CREDENCE trial studied participants with type 
2 diabetes mellitus and established chronic kidney 
disease, of whom half did not have known cardio-
vascular disease at study entry. In contrast to previ-
ous studies that have suggested reductions in major 
cardiovascular events with SGLT2 inhibitors only in 
participants with existing cardiovascular disease,5 
canagliflozin reduced the risk of major cardiovascu-
lar events and renal outcomes in both the primary 
and secondary prevention groups. This finding sug-
gests that canagliflozin can be effectively used for 
both primary and secondary prevention of major 
cardiovascular events in people with type 2 diabetes 
mellitus and chronic kidney disease and is the first 
antihyperglycemic drug to show benefit in a primary 
prevention group.
Three large cardiovascular outcomes studies have 
previously reported results in primary and secondary 
prevention groups,3,4,10–12 and a systematic review of 
all 3 trials has been published.5 In those trials, the 
treatment benefit with SGLT2 inhibition compared 
with placebo in reducing cardiovascular outcomes was 
evident primarily in participants with established car-
diovascular disease, with no benefit observed in those 
without known cardiovascular disease, although in 
the CANVAS Program (Canagliflozin Cardiovascular 
Assessment Study) there was no evidence of signifi-
cant statistical heterogeneity in the treatment effect 
of canagliflozin compared with placebo in cardiovas-
cular outcomes in primary and secondary prevention 
groups.12 In CREDENCE, a robust and consistent re-
duction in cardiovascular events and renal events was 
observed in both the primary and secondary preven-
tion groups, suggesting that chronic kidney disease it-
self is a potent risk marker not only for cardiovascular 
events—the primary prevention group in CREDENCE 
was not at a low risk for cardiovascular events—but 
also for treatment benefit. The event rates for both 
cardiovascular and renal outcomes were generally sim-
ilar or higher in CREDENCE than in the other trials as 
A
B
Figure 2. Effects of canagliflozin on car-
diovascular outcomes in the primary and 
secondary prevention cohorts. 
A, Cardiovascular death and hospitalization for 
heart failure. B, Cardiovascular death, nonfatal 
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expected because 50% had known cardiovascular dis-
ease and 60% had eGFR <60 mL·min−1·1.73 m−2. This 
high baseline risk may explain, in part, the benefits 
in the primary prevention group seen in CREDENCE 
compared with the other studies.
Canagliflozin reduced major cardiovascular out-
comes with consistency across the cardiovascular com-
posites and individual component outcomes. This is 
similar to the findings of the CANVAS Program4 and 
suggests that clinicians can expect consistent reduc-
tions in the individual components of the composite 
major cardiovascular events outcome when using cana-
gliflozin across broad patient populations defined by 
clinical characteristics, extent of diabetes mellitus, and 
renal function.
The CREDENCE population was at higher risk for 
cardiovascular events compared with previous SGLT2 
inhibitor trials,3,4,11 given the targeted enrollment of 
participants with type 2 diabetes mellitus with estab-
lished chronic kidney disease. As shown previously,5 
the absolute and relative treatment effects of cana-
gliflozin and other SGLT2 inhibitors were more robust 
for hospitalization for heart failure compared with ath-
erosclerotic events, and these effects were consistent 
regardless of the presence or absence of preexisting 
cardiovascular disease across all completed studies, 
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Figure 3. Effects of canagliflozin on renal and cardiovascular outcomes in the secondary and primary prevention cohorts. 
eGFR indicates estimated glomerular filtration rate; and ESKD, end-stage kidney disease. *Diamonds represent the result of a single analysis of the full cohort. 
†The primary composite outcome included ESKD, doubling of serum creatinine, or renal or cardiovascular death. ‡Hazard ratios and 95% CIs were calculated for 
outcomes with >10 events. §The cardiovascular composite outcome included cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization 
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including the present trial. Several mechanisms have 
been proposed to explain the effect of SGLT2 inhibi-
tors on hospitalization for heart failure, including a na-
triuretic effect, improvement in blood pressure, lower 
weight, improved glucose levels, and altered myocar-
dial energy metabolism.13 Further study is needed to 
better understand the mechanisms or to clarify the 
relative contribution of the effects on intermediaries 
and the impact on clinical outcomes.
These results have important clinical implications. 
First, clinicians considering treatment for cardiovascu-
lar and renal protection of patients like those enrolled 
in CREDENCE should do so regardless of whether 
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Figure 4. Effects of canagliflozin vs placebo on cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke across patient subgroups. 
BMI indicates body mass index; BP, blood pressure; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; and UACR, urine 
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protection against major cardiovascular events even in 
those without preexisting cardiovascular disease. The 
NNT for cardiovascular outcomes ranged from 29 to 40 
in the overall population, 36 to 53 in the primary 
prevention group, and 21 to 44 in the secondary 
prevention group. Second, canagliflozin is currently 
approved by the US Food and Drug Administration 
and other regulatory agencies for the prevention 
of cardiovascular outcomes in patients with eGFR 
>45 mL·min−1·1.73 m−2. Data from the CREDENCE trial, 
the first study of SGLT2 inhibitors dedicated to evalu-
ate renal outcomes specifically in patients with diabe-
tes mellitus with albuminuric nephropathy, support the 
initiation of canagliflozin in patients with eGFR as low 
as 30 mL·min−1·1.73 m−2 and continuation until renal 
replacement therapy is initiated or side effects occur, 
which was the approach used in CREDENCE. The data 
also suggest benefit in patients with glycated hemo-
globin as low as 6.5%, which is below the American 
Diabetes Association recommended target of 7.0% 
for most patients.14 These robust results in CREDENCE 
were observed with an overall safety profile consistent 
with known side effects of canagliflozin and no signifi-
cant difference in fractures or amputations.
These analyses have several limitations. The trial was 
not designed with adequate statistical power to evalu-
ate outcomes in subgroups defined by known cardio-
vascular disease or in further subgroups defined by lev-
el of renal function. Although baseline characteristics 
were representative of the typical patient with type 2 
diabetes mellitus and chronic kidney disease, the car-
diovascular history was provided by site investigators 
after a review of available medical records or partici-
pant interviews; no formal assessment of cardiovascu-
lar disease was performed in participants at baseline. 
Some participants in the primary prevention group may 
have had cardiovascular disease that was not clinically 
evident.
In participants with type 2 diabetes mellitus and 
chronic kidney disease, canagliflozin reduced major car-
diovascular events and renal outcomes across a broad 
spectrum of subgroups, including those without cardio-
vascular disease at baseline.
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